Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model

Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis...

Full description

Saved in:
Bibliographic Details
Published in:Turkish journal of haematology 2017-06, Vol.34 (2), p.137-142
Main Authors: Cengiz Seval, Güldane, Özkavukçu, Sinan, Seval, Murat, Aylı, Meltem
Format: Article
Language:English
Subjects:
Animals
chronic myeloid leukemia
Drinking water
Female
Females
Fertility
gonads
Laboratories
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Males
Mice
mouse
Neoplasms, Experimental - drug therapy
Neoplasms, Experimental - metabolism
Neoplasms, Experimental - pathology
nilotinib
Ovarian Follicle - metabolism
Ovarian Follicle - pathology
Pregnancy
Proteins
Pyrimidines - adverse effects
Pyrimidines - pharmacology
Rodents
Spermatogenesis
Spermatogenesis - drug effects
Studies
Targeted cancer therapy
Tıp
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis by using histopathological parameters. Ten male and ten female mice were orally treated with nilotinib at 20 mg/kg body weight dissolved in drinking water daily for 2 months. When compared with the control group, a statistically significant decrease was demonstrated in the total follicle numbers of the female mice in the nilotinib group (268±110 vs. 170±60; p=0.03). Active spermatogenesis was observed in each tubule sample taken from the mice in the control and nilotinib groups. Spermatogenic activity was similar in the two groups. We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.
ISSN:1300-7777
1308-5263
DOI:10.4274/tjh.2016.0092